Thursday, October 24, 2013
Preclinical and clinical studies that drove CAR-based T cell therapeutic
development. About 20
years of cumulative work in academic centers has driven adoptive T cell
therapies featuring chimeric antigen receptors (CARs) into the clinic and
caught the attention of numerous biotechs and pharmas. Clinical studies are
noted in blue.